Lead Clinical Application Specialist - Nuclear Medicine
About the job
- At least five years of imaging experience, including at least three years specifically in the PET or Nuclear Medicine modality.
- ARRT or equivalent certification specific to the Nuclear Medicine or PET modality.
- A four-year bachelor's degree from an accredited university is preferred, preferably in a technical field.
- Willingness to travel extensively, at least 80% or four to five days per week, including overnight travel and some weekends, within the United States and Canada.
- Residence within one hour of a major airport.
- Ability to register with vendor credentialing services and provide proof of immunizations, including MMR and Hepatitis, and complete drug screening.
- Proficiency with Windows, Outlook, Word, PowerPoint, and Excel, with the ability to quickly learn specialized industry-specific software.
- Deliver comprehensive clinical education to end users, including physicians, nurses, and technologists, aligned with the sales order agreement.
- Coordinate and deliver on-site and virtual customer training, including pre-training planning, patient go-live support, and post-go-live training.
- Complete documentation requirements consistently and on time throughout the pre-training through post-training phases.
- Provide pre-sale product clinical evaluations and educational sessions to potential customers as needed.
- Broaden clinical and technical skills to execute an effective training strategy.
- Maintain customer relationships through proactive communication and relay product or customer concerns and opportunities to Management, Sales, Marketing, and Technical Support.
- Represent MIM as a Clinical Application Specialist by explaining clinical and complex technical information to radiologists, physicists, facility management, and other staff levels.
- Apply a basic understanding of business drivers and how the work integrates with internal teams.
- Communicate product intelligence, including customer concerns, opportunities, and competitive information, to appropriate internal parties.
- Adhere to a compliant, ethical culture and the organization's ethical standards.
- Exceptional interpersonal and communication skills to build strong customer relationships.
- Clinical and technical knowledge to resolve issues within established procedures and judgment to consult senior team members on issues outside defined parameters.
- Autonomy to make decisions within a defined framework.
- Strong organizational skills for scheduling and managing documentation requirements.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
- CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
- CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.
What critics are saying
- FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
- Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
- SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.
What makes GE Healthcare unique
- GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
- Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
- SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.
AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.
GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.